Why the study?
Does perhexiline maleate reduce anginal attacks and glyceryl trinitrate consumption in patients with angina pectoris?
Does perhexiline maleate reduce anginal attacks and glyceryl trinitrate consumption in patients with angina pectoris?
Perhexiline maleate is an effective antianginal agent that reduces anginal attacks and nitroglycerin consumption, though it causes dizziness in a significant minority of patients.
Supports perhexiline for refractory angina; confirms metabolic modulation efficacy in stable CAD.
This paper reports a double-blind trial of a new antianginal drug, perhexiline. Fifty-five patients suffering from angina pectoris were studied for periods of 12 or 24 weeks in a cross-over comparison against a placebo in four centres in the United Kingdom and Ireland. Perhexiline was effective in most patients as judged by reducing the number of anginal attacks in 84% and the consumption of glyceryl trinitrate tablets in 64%. The major side effect, dizziness, noted in one-third of the patients, may be dose/body-weight related. Perhexiline is a valuable new agent for the treatment of patients with angina, especially those who do not respond to other antianginal agents.
No takes yet. Share an insight, caveat, or question.
Burns‐Cox et al. (1971) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: